Podcasts about seton hall school

Stacey Edwards is a lawyer with a heart for people in times of crisis. Listen in as she shares 2 important topics that all us of need to have covered for our eventual passing. You've never met a lawyer like Stacey! Make sure you stay until the end to hear about the non-profit she's building that will impact the entire country! Stacey's credentials include the following: Juris Doctor, Seton Hall School of Law – 1998 Master of Science, Justice, The American University – 1995 Bachelor of Arts, Political Science, High Point University – 1990 *Member, National Academy of Elder Law Attorneys *Member, New Jersey State Bar Association: Elder & Disability Law Section; Real Property, Estate & Trust Section *Member, Somerset County Bar Association*Member, Lawyers of Distinction *New Jersey State Bar – Admitted 1999 *United States District Court of New Jersey – Admitted 1999 *Supreme Court of the United States – Admitted 2012 To connect with Stacey: Web site: https://edwardsestatelaw.com Instagram: https://www.instagram.com/edwardsestatelaw LinkedIn: linkedin.com/in/staceyedwardslaw Facebook: https://www.facebook.com/edwardsestateelderlaw To start your decluttering journey: https://thedeclutteringclub.com/  Follow Decluttering Club on Instagram: https://instagram.com/declutteringclub  Join Us on Facebook: https://www.facebook.com/EarlybirdMom Check out more tips on our YouTube channel: https://www.youtube.com/@DeclutteringClub

Building The Next Generation of Healthcare Leaders with Michellene Davis. My next podcast guest, Michellene Davis, Esq assumed the role of President and Chief Executive Officer of National Medical Fellowships, Inc., (NMF) in May of 2021. Founded in 1946, NMF was one of America's first diversity organizations and remains the only national organization advancing health equity at the intersection of wealth and health. It provides scholarships to Black, Indigenous, and People of Color (BIPOC) medical and health professions students underrepresented in medicine to ensure equity of access to culturally competent, high-quality health care. NMF also increases the number of BIPOC clinician leaders to diversify clinical trials. Davis is named among Modern Healthcare magazine's Top 25 Most Influential Minority Leaders in Healthcare and Becker's Hospital Review's Top113 Great Leaders in Healthcare 2022 and Top 50 African Americans to Know in Healthcare. The National Association of Health Services Executives awarded her their 2021 Senior Health Care Executive Award.  Davis most recently served as Executive Vice President and Chief Corporate Affairs Officer at RWJ Barnabas Health, the largest academic medical center system in New Jersey and one of the largest in the nation. She was the first African American in state history to serve as Chief Policy Counsel to former New Jersey Governor Jon S. Corzine, the first African American and only the second woman to serve as New Jersey State Treasurer.  Ms. Davis began her legal career as a trial litigator, is an Honors graduate of Seton Hall University, and holds a Juris Doctorate from Seton Hall School of Law. She holds Executive Education Certificates in Corporate Social Responsibility from the Harvard Business School and in Social Impact Strategy from the Wharton School of Business. In this interview we cover: ~Michellene Davis' journey to becoming President and CEO of NMF ~Explore why having BIPOC (Black, Indigenous, and People of Color) physicians is vital to healthcare ~How the ability to recruit and retain diverse healthcare leaders would impact healthcare disparities ~What is NMF's approach to reducing healthcare disparities and what would it take for other organizations to support diversity in healthcare?  ~NMF's 7 pillars If you're ready to transition into a leadership role and make an impact in healthcare by supporting your colleagues, reducing healthcare disparities, and improving outcomes, schedule a discovery call with me at www.schedulewithdrlisa.com Download our free Ebook 'The 10 Steps You Need to Transition into a Leadership Role'

Vance Crowe is a communications consultant that has worked for corporations and international organizations around the world. He has spoken before more than 150,000 people, answering questions about some of the most sophisticated and controversial technologies in the modern age.  Vance helps organizations realize why the general public doesn't agree with their perspective and offers new ways to communicate effectively, resolve disagreements, and build rapport with critics and stakeholders.    Vance is the former Director of Millennial Engagement for Monsanto. He previously worked as a Communications Strategist for the World Bank Group, as a U.S. Peace Corps Volunteer stationed in Kenya, as a Communications Coordinator at a National Public Radio affiliate in Northern California, and as a deckhand on an eco-tourism ship that traveled the Western Hemisphere.  His stories and lessons illuminate aspects of communications that remain hidden to most people. Vance holds a degree in communications from Marquette University and a master's degree in cross-cultural negotiations from the Seton Hall School of Diplomacy.  Vance is the CEO of Articulate Ventures LLC. a boutique public relations and marketing firm in Saint Louis, Missouri.

Vance Crowe is the CEO of Articulate Ventures, a strategic communications company in Saint Louis, Missouri and is a non-resident fellow at the Center for Conflict and Peace Studies at the Seton Hall School of Diplomacy. Learn more about your ad choices. Visit megaphone.fm/adchoices

Founded in 1946, NMF was one of America's first diversity organizations. Today, NMF remains the only the only national organization solely dedicated to providing scholarships to medical and health professions students in all groups underrepresented in healthcare. Ms. Davis comes to NMF from RWJBarnabas Health, the largest academic medical center system in New Jersey, where she served as Executive Vice President and Chief Corporate Affairs Officer. Ms. Davis created and led Social Impact and Community Investment, an equity-centered, policy-led community health practice dedicated to addressing the social and political determinants of health. During her tenure there her portfolio consisted of: Policy Development and Government Affairs, Healthy Living and Community Engagement, Employee Wellness, Marketing, Communications, External and Corporate Affairs and, Global Health. She is the creator of the RWJBarnabas Health Women's Leadership Alliance, the Young Professional Advisory Council, and the Corporate Institute for Internship. The Social Impact and Community Investment Practice was created to leverage the system's range of assets to advance a culture of health and lift the quality of life in New Jersey communities. With a programmatic emphasis on ensuring health equity, the practice spearheads innovative social impact and external affairs initiatives that address the social, economic, and environmental conditions that have a significant impact on health outcomes. The policy arm leads the practice as it seeks to change systems, structures, and policies to create a more equitable future for all New Jerseyans. Before joining RWJBarnabas Health, Ms. Davis served as Chief Policy Counsel to former New Jersey Governor Jon Corzine, where she was the first African American to serve in this position in state history. She was the first African American and only the second women to serve as Acting New Jersey State Treasurer responsible for a state budget of over $30 billion dollars. She was the youngest person to serve as Executive Director of the New Jersey Lottery in state history and served as a senior policy advisor in the New Jersey Department of Health and Senior Services. She has a proven record of supporting the equitable building of community wealth and health throughout her career and, while Acting State Treasurer of New Jersey, founded the New Jersey Department of the Treasury's Office of Supplier Diversity and Division of Minority and Women Owned Businesses. Ms. Davis is also active in civic engagement in the local and the global community. Nationally, she serves on the Boards of The Democracy Collaborative and The Root Cause Coalition and on the Health Anchor Network Founding Design Team; Root Cause Coalition National Advisory Board and United Way ALICE National and Building Healthy Places Advisory Councils. Globally, she is a member of the Board of Directors of the International Black Women's Public Policy Institute. She is the President Emeritus of Executive Women of New Jersey, the state's premier organization for senior level executive women in business, Chair of Academic Affairs for the Joint Board of Rutgers-Rowan Universities; Treasurer of the New Jersey Performing Arts Center Women's Association; and is on the boards of the New Jersey Women Lawyers Association; Rutgers Institute for Women's Leadership; New Jersey Bipartisan Coalition for Women's Appointments; Caucus Educational Trust and the New Jersey Legislative Black Caucus Foundation. Ms. Davis began her legal career as a trial litigator, is an Honors graduate of Seton Hall University and holds a Juris Doctorate from Seton Hall School of Law. She holds Executive Education Certificates in Corporate Social Responsibility from the Harvard Business School and in Social Impact Strategy from the Wharton School of Business. Special Guest: Michellene Davis.

Founded in 1946, NMF was one of America's first diversity organizations. Today, NMF remains the only the only national organization solely dedicated to providing scholarships to medical and health professions students in all groups underrepresented in healthcare. Ms. Davis comes to NMF from RWJBarnabas Health, the largest academic medical center system in New Jersey, where she served as Executive Vice President and Chief Corporate Affairs Officer. Ms. Davis created and led Social Impact and Community Investment, an equity-centered, policy-led community health practice dedicated to addressing the social and political determinants of health. During her tenure there her portfolio consisted of: Policy Development and Government Affairs, Healthy Living and Community Engagement, Employee Wellness, Marketing, Communications, External and Corporate Affairs and, Global Health. She is the creator of the RWJBarnabas Health Women's Leadership Alliance, the Young Professional Advisory Council, and the Corporate Institute for Internship. The Social Impact and Community Investment Practice was created to leverage the system's range of assets to advance a culture of health and lift the quality of life in New Jersey communities. With a programmatic emphasis on ensuring health equity, the practice spearheads innovative social impact and external affairs initiatives that address the social, economic, and environmental conditions that have a significant impact on health outcomes. The policy arm leads the practice as it seeks to change systems, structures, and policies to create a more equitable future for all New Jerseyans. Before joining RWJBarnabas Health, Ms. Davis served as Chief Policy Counsel to former New Jersey Governor Jon Corzine, where she was the first African American to serve in this position in state history. She was the first African American and only the second women to serve as Acting New Jersey State Treasurer responsible for a state budget of over $30 billion dollars. She was the youngest person to serve as Executive Director of the New Jersey Lottery in state history and served as a senior policy advisor in the New Jersey Department of Health and Senior Services. She has a proven record of supporting the equitable building of community wealth and health throughout her career and, while Acting State Treasurer of New Jersey, founded the New Jersey Department of the Treasury's Office of Supplier Diversity and Division of Minority and Women Owned Businesses. Ms. Davis is also active in civic engagement in the local and the global community. Nationally, she serves on the Boards of The Democracy Collaborative and The Root Cause Coalition and on the Health Anchor Network Founding Design Team; Root Cause Coalition National Advisory Board and United Way ALICE National and Building Healthy Places Advisory Councils. Globally, she is a member of the Board of Directors of the International Black Women's Public Policy Institute. She is the President Emeritus of Executive Women of New Jersey, the state's premier organization for senior level executive women in business, Chair of Academic Affairs for the Joint Board of Rutgers-Rowan Universities; Treasurer of the New Jersey Performing Arts Center Women's Association; and is on the boards of the New Jersey Women Lawyers Association; Rutgers Institute for Women's Leadership; New Jersey Bipartisan Coalition for Women's Appointments; Caucus Educational Trust and the New Jersey Legislative Black Caucus Foundation. Ms. Davis began her legal career as a trial litigator, is an Honors graduate of Seton Hall University and holds a Juris Doctorate from Seton Hall School of Law. She holds Executive Education Certificates in Corporate Social Responsibility from the Harvard Business School and in Social Impact Strategy from the Wharton School of Business. Special Guest: Michellene Davis.

Thank you for listeningFarm4Profit episode vs Farm4Fun EpisodeThank you again for suggesting topics for us to talk about on the podcast and keep them coming.  Send those to farm4profitllc@gmail.com or find us all over social media.We greatly appreciate your help in growing our audience.The listener review today is brought to you by Outback Wraps.  They help you easily connect equipment with their hydraulic hose markers with their simple identification system. And now their new SNAKE collection for bundling and containing is available by the box of 80 feet!  Use Promo Code _______ for _____% off at outbackwrap.com@uhfdrgbnnk ***** – Best podcast out there…Farm for fun is equally fun and educational. You can trust these guys for a good laugh and some light educationCommercial: John DeereWhat's Working in AGFarm RescueTips for negotiating with landlords, suppliers, buyers, and everyone else.Vance Crowe is a communications consultant that has worked for corporations and international organizations around the world. He has spoken before more than 150,000 people, answering questions about some of the most sophisticated and controversial technologies in the modern age.  Vance is the former Director of Millennial Engagement for Monsanto. He previously worked as a Communications Strategist for the World Bank Group, as a U.S. Peace Corps Volunteer stationed in Kenya, as a Communications Coordinator at a National Public Radio affiliate in Northern California.Vance holds a degree in communications from Marquette University and a master's degree in cross-cultural negotiations from the Seton Hall School of Diplomacy. He's here today to help make the complex idea of negotiating simple for all of us to understand.General QuestionsThis is now the second time we here at Farm4Profit have focused on this topic.  Why is this so important?Cash rentInputsEquipmentSalesLaborCan anyone become good at negotiating?What does it take to be good at it?Is there an art to asking good questions?How can I become good at asking questions?How can we start a negotiation with a leg up?Seems like no one wants to “show their cards” first….Is that the right way?How do we recover if we feel like we are behind or losing?What are smart tradeoffs or ways to compromise?Should we even wany compromise?What is the 51/49 rule, why is it important?Is this the same as never split the difference?Are win-win deals really losers?Are there any sure-fire tips you can provide the listeners to improve their skills?5 key tips everyone needs to knowHow does body language play into the negotiation? Do you have any exciting stories what would grab the listener's ear?Is there anything else our listener needs to know about negotiating?Situational QuestionsNegotiations with someone who we believe has the upper hand.  Negotiating with landlord who owns the farm ground.  The idea is that owner could rent it out to any other farmer in the neighborhood if we don't pay their price (which is probably too high).  Control over a land base is key in agriculture and the reason many over pay cash rent on land.Negotiations with Ag retailers who provide chemicals, fertilizer, seed, and more.Negotiations with a salesperson who usually doesn't have the final say.  Most of the time is a large company with what appears to be set prices.  Farmers just succumb to what is offered thinking it's their only option.Negotiations with AG product purchasers.  How do we get more money for the products we produce?Most farmers don't sell directly to the consumer, so they market their product to processors.  These can be grain elevators or meat packing facilities that have a combination of price x weight component with a basis factor for delivery and end product.  How can we negotiate the sale to ensure we aren't leaving any money on the table in the end?Negotiations with friends who also sell a product or provide a service. Agriculture is a tight knit group.  More than likely the people you buy from in your network are also your friends.  We don't want to hurt their feelings, but also know the key to our future is to be a profitable farmer.Negotiations with family for time and labor.The common question around the AG world is how to balance farm and family.  Our observations are some farmers feel guilty for spending more time on their work than their family.  We believe there should be a balance, but balance doesn't always mean equal.  Most of the time the feeling of guilt comes from misrepresented expectations or abilities.  How do we more effectively win discussions/conversations/negotiations about where our time is spent with family?SummaryChallengeDon't forget about the BW Fusion fall incentive for signing up and purchasing 500 acres of meltdown and the 401 team then you get a free field in 365.  Also remember that they combine their best-in-class products along with the 365 soil and tissue program to provide growers the tools necessary to address limiting factors in real time.  Just like 365 Your reviews are how we monitor our podcast in real time.Reminder to like, rate, and review.  Please don't hesitate to share the “Mullet of Podcasts” with your friends.  We look forward to sharing more time with you next week on our Farm4Fun Episode.Remember, everything is negotiable.Don't narrow a negotiation down to just one issue. Develop as many issues or negotiable deal points as you can and then juggle in additional deal points if you and the other party lock onto one issue.Crystallize your vision of the outcome. The counterpart who can visualize the end result will most likely be the one who guides the negotiation.Prepare in advance. Information is power. Obtain as much information as possible beforehand to make sure you understand the value of what you are negotiating. Remember, very few negotiations begin when the counterparts arrive at the table.Ask questions. Clarify information you do not understand. Determine both the implicit and explicit needs of your counterpart.Listen. When you do a good job listening, you not only gain new ideas for creating win/win outcomes but also make your counterpart feel cared for and valued. This also allows you to find out what the other party wants. If you assume that his or her wants and needs are the same as yours, you will have the attitude that only one of you can “win” the negotiation.Set a goal for each deal point. Define your minimum level of acceptance for each goal. If you aren't clear on your goals, you will end up reacting to the propositions of your counterpart.Aim your aspirations high. Your aspirations will likely be the single most important factor in determining the outcome of the negotiation. You can aim high just as easily as you can aim low.Develop options and strategies. Successful people are those who have the greatest number of viable alternatives. Similarly, successful negotiators are those who have the most strategies they can use to turn their options into reality.Think like a dolphin. The dolphin is the only mammal who can swim in a sea of sharks or in a sea of carp. Dolphins are able to adapt their strategies and behaviors to their counterparts. Remember, even when negotiating with a shark, you have an option–you can walk away!Be honest and fair. In life, what goes around comes around. The goal in creating win/win outcomes is to have both counterparts feel that their needs and goals have been met, so that they will be willing to come back to the table and negotiate again. An atmosphere of trust reduces the time required to create win/win outcomes.Never accept the first offer. Often, the other party will make an offer that he or she thinks you will refuse just to see how firm you are on key issues. Chances are, if you don't have to fight a little for what you want, you won't get the best deal.Deal from strength if you can. If that's not possible, at least create the appearance of strength. If the other party thinks you have no reason to compromise in your demands, he or she is less likely to ask you to.Find out what the other party wants. Concede slowly, and call a concession a concession. Giving in too easily tells the other party that you will probably be open to accepting even more concessions.Be cooperative and friendly.Avoid being abrasive or combative, which often breaks down negotiations.Use the power of competition. Someone who thinks it's necessary to compete for your business may be willing to give away more than he or she originally intended. Sometimes just the threat of competition is enough to encourage concessions.https://peterstark.com/15-rules-of-negotiation/

We live in a social world that is filtered and constructed to highlight the “good stuff.” And while I am SUPER into recognizing and lifting the good (as you know), sometimes it keeps us from truly understanding or realizing what another might be experiencing. This can keep us from being known and makes it difficult to establish meaningful connections with others. It also perpetuates an inaccurate narrative of each other. This week I talk with Rachel DeAlto, relationship expert, about presenting more authentically in life and re-entering and establishing connections post COVID-19. Let’s do this! Guest Bio: Rachel has been a relationship expert on Seasons 4 & 5 of Lifetime’s Married at First Sight and TLC’s Kate+Date. She has represented Match, Comfort Suites, and TD Bank as a national spokesperson, and currently works with Match as its Chief Dating Expert. She has shared her expertise with audiences on The TODAY Show, Good Morning America, CNN/HLN, Access Hollywood Live, The Steve Harvey Show, and Fox News. Rachel has also presented three TEDx talks, her most recent: Being Authentic in A Filtered World which is presently featured on TED.com. Rachel is a graduate of Seton Hall School of Law and is completing her Master’s in Psychology at Arizona State University. She is a certified coach and trained in hypnotherapy and meditation. She’s truly a powerhouse and a lot of fun! IG, Clubhouse: @racheldealto

"When you're talking about how to impact the intransigent minority, you can't add more force with force. You have to recognize the intransigent minority is not the group you're negotiating with. You're negotiating with the group that's in the middle. And what they want to know is: do you understand the concerns of the people on the other side? Because if you do understand their point of view and you can show why your point of view addresses their needs, but yet they're still happy, then you have a far better chance of winning over the massive middle." – Vance Crowe What you will learn: Millennial Engagement for Monsanto; The way we connect with consumers; Storytelling; Knowledge gaps; The intransigent minority; Long-term trends; Social media; Negotiation; The Dunning-Kruger Effect; Documentaries; Biggest lessons from his podcast; The Peter Thiel Paradox; Communications. Meet the guest: Vance Crowe is a communications consultant that has worked for corporations and international organizations around the world. He is the former Director of Millennial Engagement for Monsanto. He previously worked as a Communications Strategist for the World Bank Group, as a U.S. Peace Corps Volunteer stationed in Kenya, as a Communications Coordinator at a National Public Radio affiliate in Northern California, and as a deckhand on an eco-tourism ship that traveled the Western Hemisphere. Vance holds a degree in communications from Marquette University and a master's degree in cross-cultural negotiations from the Seton Hall School of Diplomacy.

Vance Crowe interviews his graduate school mentor, Zheng Wang. They discuss cultural interpretations about masks, and why China and the US have different Coronavirus results.  Zheng Wang taught me a great deal about other ways of thinking about the world.  He took far more interest in my work than any other professor I've ever met.  He pushed me to submit higher quality work, he taught me different emotional and social frameworks to use to better understand conflict, and he made me understand the world in a much more nuanced way.  Vance and Zheng Wang discuss the core of the US China cultural misunderstandings and discuss the difference in education systems.  The two talk about the leaders of China Xi Jinping and Donald Trump discussing the national motto's adopted by the two leaders.Zheng Wang Ph.D. is the director for the Center for Peace and Conflict Resolution at the Seton Hall School of Diplomacy and International Relations.  To support the podcast, meet others in the Articulate Ventures Network, and join the Articulate Ventures Book Club: https://www.articulate.venturesThis month's book is 1984 by George Orwell.  We will hold the book club discussion on Sunday July 26, 2020 at 7:30 pm

It’s always interesting to dive into the success of lawyers who began their life journeys outside of the United States. Christina’s guest today is Rawan Hmoud, Esq., an attorney in Jersey City, New Jersey practicing divorce and family law. Rawan, the oldest of 4, was born in Jordan and moved around the Middle East until the Gulf War forced her and her family to move to Wayne, New Jersey when she was 11-years-old. From a young age, she knew that she liked arguing and looking at problems from a different perspective. Years later, Rawan completed her undergrad at Rutgers University, law school at Seton Hall School of Law, and began her journey to becoming the incredible lawyer that she is today! In this episode, we talk about… Rawan’s background and her journey to becoming a lawyer Lessons learned from working customer service jobs while being a full-time student Getting her first taste of court and landing an amazing clerkship Litigation is not easy but remains a necessary step in many cases Dealing with cases that cross state and international lines Diving into Rawan’s life outside of practicing law Breaking down the exciting activities on Rawan’s bucket list Rawan’s not-so-secret passion for driving Links to resources: Rawan Hmoud, Esq., Offit|Kurman Attorneys at Law Reach out to Rawan on LinkedIn or via email: rhmoud@offitkurman.com Instagram.com/wakeupcallthepodcast Facebook.com/wakeupcallthepodcast Twitter.com/wakeupcallpod If you want to know more about me and sign up for my newsletter: www.ChristinaPrevite.com If you are a #FEMSQUIRE or female entrepreneur and you want to appear as a guest on Wake Up Call, let's talk! Please email me at ChristinaEsq@iCloud.com.

  Jeff: Welcome back to Emplify, the podcast corollary to EB Medicine's Emergency Medicine Practice. I'm Jeff Nusbaum, and I'm back with my co-host, Nachi Gupta. This month, we're talking about a topic that is ripe for review this time of year. We're talking Influenza… Diagnosis and Management. Nachi: Very appropriate as the cold is settling in here in NYC and we're already starting to see more cases of influenza. Remember that as you listen through the episode, the means we're about to cover one of the CME questions for those of you listening at home with the print issue handy. Jeff: This month's issue was authored by Dr. Al Giwa of the Icahn School of Medicine at Mount Sinai, Dr. Chinwe Ogedegbe of the Seton Hall School of Medicine, and Dr. Charles Murphy of Metrowest Medical Center. Nachi: And this issue was peer reviewed by Dr. Michael Abraham of the University of Maryland School of Medicine and by Dr. Dan Egan, Vice Chair of Education of the Department of Emergency Medicine at Columbia University. Jeff: The information contained in this article comes from articles found on pubmed, the cochrane database, center for disease control, and the world health organization. I'd say that's a pretty reputable group of sources. Additionally, guidelines were reviewed from the american college of emergency physicians, infectious disease society of america, and the american academy of pediatrics. Nachi: Some brief history here to get us started -- did you know that in 1918/1919, during the influenza pandemic, about one third of the world's population was infected with influenza? Jeff: That's wild. How do they even know that? Nachi: Not sure, but also worth noting -- an estimated 50 million people died during that pandemic. Jeff: Clearly a deadly disease. Sadly, that wasn't the last major outbreak… fifty years later the 1968 hong kong influenza pandemic, H3N2, took between 1 and 4 million lives. Nachi: And just last year we saw the 2017-2018 influenza epidemic with record-breaking ED visits. This was the deadliest season since 1976 with at least 80,000 deaths. Jeff: The reason for this is multifactorial. The combination of particularly mutagenic strains causing low vaccine effectiveness, along with decreased production of IV fluids and antiviral medication because of the hurricane, all played a role in last winter's disastrous epidemic. Nachi: Overall we're looking at a rise in influenza related deaths with over 30,000 deaths annually in the US attributed to influenza in recent years. The ED plays a key role in outbreaks, since containment relies on early and rapid identification and treatment. Jeff: In addition to the mortality you just cited, influenza also causes a tremendous strain on society. The CDC estimates that epidemics cost 10 billion dollars per year. They also estimate that an epidemic is responsible for 3 million hospitalized days and 31 million outpatient visits each year. Nachi: It is thought that up to 20% of the US population has been infected with influenza in the winter months, disproportionately hitting the young and elderly. Deaths from influenza have been increasing over the last 20 years, likely in part due to a growing elderly population. Jeff: And naturally, the deaths that we see from influenza also disproportionately affect the elderly, with up to 90% occurring in those 65 or older. Nachi: Though most of our listeners probably know the difference between an influenza epidemic and pandemic, let's review it anyway. When the number of cases of influenza is higher than what would be expected in a region, an epidemic is declared. When the occurrence of disease is on a worldwide spectrum, the term pandemic is used. Jeff: I think that's enough epidemiology for now. Let's get started with the basics of the influenza virus. Influenza is spread primarily through direct person-to-person contact via expelled respiratory secretions.

  Jeff: Welcome back to Emplify, the podcast corollary to EB Medicine’s Emergency Medicine Practice. I’m Jeff Nusbaum, and I’m back with my co-host, Nachi Gupta. This month, we’re talking about a topic that is ripe for review this time of year. We’re talking Influenza… Diagnosis and Management. Nachi: Very appropriate as the cold is settling in here in NYC and we’re already starting to see more cases of influenza. Remember that as you listen through the episode, the means we’re about to cover one of the CME questions for those of you listening at home with the print issue handy. Jeff: This month’s issue was authored by Dr. Al Giwa of the Icahn School of Medicine at Mount Sinai, Dr. Chinwe Ogedegbe of the Seton Hall School of Medicine, and Dr. Charles Murphy of Metrowest Medical Center. Nachi: And this issue was peer reviewed by Dr. Michael Abraham of the University of Maryland School of Medicine and by Dr. Dan Egan, Vice Chair of Education of the Department of Emergency Medicine at Columbia University. Jeff: The information contained in this article comes from articles found on pubmed, the cochrane database, center for disease control, and the world health organization. I’d say that’s a pretty reputable group of sources. Additionally, guidelines were reviewed from the american college of emergency physicians, infectious disease society of america, and the american academy of pediatrics. Nachi: Some brief history here to get us started -- did you know that in 1918/1919, during the influenza pandemic, about one third of the world’s population was infected with influenza? Jeff: That’s wild. How do they even know that? Nachi: Not sure, but also worth noting -- an estimated 50 million people died during that pandemic. Jeff: Clearly a deadly disease. Sadly, that wasn’t the last major outbreak… fifty years later the 1968 hong kong influenza pandemic, H3N2, took between 1 and 4 million lives. Nachi: And just last year we saw the 2017-2018 influenza epidemic with record-breaking ED visits. This was the deadliest season since 1976 with at least 80,000 deaths. Jeff: The reason for this is multifactorial. The combination of particularly mutagenic strains causing low vaccine effectiveness, along with decreased production of IV fluids and antiviral medication because of the hurricane, all played a role in last winter’s disastrous epidemic. Nachi: Overall we’re looking at a rise in influenza related deaths with over 30,000 deaths annually in the US attributed to influenza in recent years. The ED plays a key role in outbreaks, since containment relies on early and rapid identification and treatment. Jeff: In addition to the mortality you just cited, influenza also causes a tremendous strain on society. The CDC estimates that epidemics cost 10 billion dollars per year. They also estimate that an epidemic is responsible for 3 million hospitalized days and 31 million outpatient visits each year. Nachi: It is thought that up to 20% of the US population has been infected with influenza in the winter months, disproportionately hitting the young and elderly. Deaths from influenza have been increasing over the last 20 years, likely in part due to a growing elderly population. Jeff: And naturally, the deaths that we see from influenza also disproportionately affect the elderly, with up to 90% occurring in those 65 or older. Nachi: Though most of our listeners probably know the difference between an influenza epidemic and pandemic, let’s review it anyway. When the number of cases of influenza is higher than what would be expected in a region, an epidemic is declared. When the occurrence of disease is on a worldwide spectrum, the term pandemic is used. Jeff: I think that’s enough epidemiology for now. Let’s get started with the basics of the influenza virus. Influenza is spread primarily through direct person-to-person contact via expelled respiratory secretions. It is most active in the winter months, but can be seen year-round. Nachi: The influenza virus is a spherical RNA-based virus of the orthomyxoviridae family. The RNA core is associated with a nucleoprotein antigen. Variations of this antigen have led to the the 3 primary subgroups -- influenza A, B, and C, with influenza A being the most common. Jeff: Influenza B is less frequent, but is more frequently associated with epidemics. And Influenza C is the form least likely to infect humans -- it is also milder than both influenza A or B. Nachi: But back to Influenza A - it can be further classified based on its transmembrane or surface proteins, hemagglutinin and neuraminidase - or H and N for short. There are actually 16 different H subtypes and 9 different N subtypes, but only H1, H2, H3, and N1 and N2 have caused epidemic disease. Jeff: Two terms worth learning here are antigen drift and anitgen shift. Antigen drift refers to small point mutations to the viral genes that code for H and N. Antigen shift is a much more radical change, with reassortment of viral genes. When cells are infected by 2 or more strains, a new strain can emerge after genetic reassortment. Nachi: With antigen shift, some immunity may be maintained within a population infected by a similar subtype previously. With antigen drift, there is loss of immunity from prior infection. Jeff: The appearance of new strains of influenza typically involves an animal host, like pigs, horses, or birds. This is why you might be hear a strain called “swine flu”, “equine flu”, or “avian flu”. Close proximity with these animals facilitates co-infection and genetic reassortment. Nachi: I think that’s enough basic biology for now, let’s move on to pathophysiology. When inhaled, the influenza virus initially infects the epithelium of the upper respiratory tract and alveolar cells of the lower respiratory tract. Viral replication occurs within 4 to 6 hours. Incubation is 18 to 72 hours. Viral shedding is usually complete roughly 7 days after infection, but can be longer in children and immunocompromised patients. Jeff: As part of the infectious process and response, there can be significant changes to the respiratory tract with inflammation and epithelial cell necrosis. This can lead to viral pneumonia, and occasionally secondary bacterial pneumonia. Nachi: The secondary bacterial pathogens that are most common include Staph aureus, Strep pneumoniae, and H influenzae. Jeff: Despite anything you may read on the internet, vaccines work and luckily influenza happens to be a pathogen which we can vaccinate against. As such, there are 3 methods approved by the FDA for producing influenza vaccines -- egg-based, cell-based, or recombinant influenza vaccine. Once the season’s most likely strains have been determined, the virus is introduced into the medium and allowed to replicate. The antigen is then purified and used to make an injection or nasal spray. Nachi: It isn’t easy to create vaccines for all strains. H3N2, for example, is particularly virulent, volatile, and mutagenic, which leads to poor prophylaxis against this particular subgroup. Jeff: In fact, a meta-analysis on vaccine effectiveness from 2004-2015 found that the pooled effectiveness against influenza B was 54%, against the H1N1 pandemic in 2009 was 61%, and against the H3N2 virus was 33%. Not surprisingly, H3N2 dominant seasons are currently associated with the highest rates of influenza cases, hospitalizations, and death. Nachi: Those are overall some low percentages. So should we still be getting vaccinated? The answer is certainly a resounding YES.. Despite poor protection from certain strains, vaccine effectiveness is still around 50% and prevents severe morbidity and mortality in those patients. Jeff: That’s right. The 2017-2018 vaccine was only 40% effective, but this still translates to 40% less severe cases and a subsequent decrease in hospitalizations and death. Nachi: But before we get into actual hospitalization, treatment, and preventing death, let’s talk about the differential. We’re not just focusing on influenza here, but any influenza like illness, since they can be hard to distinguish. The CDC defines “influenza-like illness” as a temperature > 100 F, plus cough or sore throat, in the absence of a known cause other than influenza. Jeff: Therefore, influenza should really be considered on the differential of any patient who presents to the ED with a fever and URI symptoms. The differential when considering influenza might also include mycoplasma pneumoniae, strep pneumoniae, adenovirus, RSV, rhinovirus, parainfluenza virus, legionella, and community acquired MRSA. Nachi: With the differential in mind, let’s move on to prehospital care. For the prehospital setting, there isn’t much surprising here. Stabilize and manage the respiratory status with all of your standard tools - oxygen for those with mild hypoxia and advanced airway maneuvers for those with respiratory distess. Jeff: Of note, EMS providers should use face masks themselves and place them on patients as well. As community paramedicine and mobile integrated health becomes more common, this is one potential area where EMS can potentially keep patients at home or help them seek treatment in alternate destinations to avoid subjecting crowded ED’s to the highly contagious influenza virus. Nachi: It’s also worth noting, that most communities have strategic plans in the event of a major influenza outbreak. Local, state, and federal protocols have been designed for effective care delivery. Jeff: Alright, so now that the EMS crew, wearing proper PPE of course, has delivered the patient, who is also wearing a mask, to the ED, we can begin our ED H&P. Don’t forget that patients present with a range of symptoms that vary by age. A typical history is 2-5 days of fever, nasal congestion, sore throat, and myalgias. You might see tachycardia, cough, dyspnea, and chills too. Nachi: Van Wormer et al conducted a prospective analysis of subjective symptoms to determine correlation with lab confirmed influenza. They found the most common symptoms were cough in 92%, fatigue in 91%, and nasal congestion in 84%, whereas sneezing was actually a negative predictor for influenza. Jeff: Sneezing, really? Can’t wait to get the Press-Gany results from the sneezing patient I discharge without testing for influenza based on their aggressive sneezes! Nachi: Aggressive sneezes…? I can’t wait to see your scale for that. Jeff: Hopefully I’ll have it in next month’s annals. In all seriousness, I’m not doing away with flu swabs just yet. In another retrospective study, Monto et al found that the best multivariate predictors were cough and fever with a positive predictive value of 79%. Nachi: Yet another study in children found that the predominant symptoms were fever in 95%, cough in 77%, and rhinitis in 78%. This study also suggested that the range of fever was higher in children and that GI symptoms like vomiting and diarrhea were more common in children than adults. Jeff: Aside from symptomatology, there are quite a few diagnostic tests to consider including viral culture, immunofluoresence, rt-pcr, and rapid antigen testing. The reliability of testing varies greatly depending on the type of test, quality of the sample, and the lab. During a true epidemic, formal testing might not be indicated as the decision to treat is based on treatment criteria like age, comorbidities, and severity of illness. Nachi: We’ll get to treatment in a few minutes, but diving a bit deeper into testing - there are 3 major categories of tests. The first detects influenza A only. The second detects either A or B, but cannot distinguish between them; and the third detects both influenza A and B and is subtype specific. The majority of rapid testing kits will distinguish between influenza A and B, but not all can distinguish between them. Fluorescent antibody testing by DFA is relatively rapid and yields results within 2 to 4 hours. Jeff: Viral culture and RT-PCR remain the gold standard, but both require more time and money, as well as a specialized lab. As a result, rapid testing modalities are recommended. Multiple studies have shown significant benefit to the usefulness of positive results on rapid testing. It’s safe to say that at a minimum, rapid testing helps decrease delays in treatment and management. Nachi: Looking a bit further into the testing characteristics, don’t forget that the positive predictive value of testing is affected by the prevalence of influenza. In periods of low influenza activity (as in the summer), a rapid test will have low PPV and high NPV. The test is more likely to yield false positive results -- up to 50% according to one study when prevalence is below 5%. Jeff: And conversely, in periods of high influenza activity, a rapid test will have higher PPV and lower NPV, and it is more likely to produce a false negative result. Nachi: In one prospective study of patients who presented with influenza-like illness during peak season, rapid testing was found to be no better than clinical judgement. During these times, it’s probably better to reserve testing for extremely ill patients in whom diagnostic closure is particularly important. And since the quality of the specimen remains important, empiric treatment of critically ill patients should still be considered. Jeff: Which is a perfect segway into our next topic - treatment, which is certainly the most interesting section of this article. To start off -- for mild to moderate disease and no underlying high risk conditions, supportive therapy is usually sufficient. Nachi: Antiviral therapy is reserved for those with a predicted severe disease course or with high risk conditions like long-standing pulmonary disease, pregnancy, immunocompromise, or even just being elderly. Jeff: Note to self, avoid being elderly. Nachi: Good luck with that. Anyway, early treatment with antivirals has been shown to reduce influenza-related complications in both children and adults. Jeff: Once you’ve decided to treat the patient, there are two primary classes of antivirals -- adamantane derivatives and neuraminidase inhibitors. Oh and then there is a new single dose oral antiviral that was just approved by the FDA… baloxavir marboxil (or xofluza), which is in a class of its own -- a polymerase endonuclease inhibitor. Nachi: The oldest class, the adamantane derivatives, includes amantadine and rimantadine. Then the newer class of neuraminidase inhibitors includes oseltamavir (which is taken by mouth), zanamavir (which is inhaled), and peramivir (which is administered by IV). Jeff: Oseltamavir is currently approved for patients of all ages. A 2015 meta analysis showed that the intention-to-treat infected population had a shorter time to alleviation of all symptoms from 123 hours to 98 hours. That’s over a day less of symptoms, not bad! There were also fewer lower respiratory tract complications requiring antibiotics and fewer admissions for any cause. Really, not bad! Nachi: Zanamavir is approved for patients 7 and older -- or for children 5 or older for disease prevention. Zanamavir has been associated with possible bronchospasm and is contraindicated in patients with reactive airway disease. Jeff: Peramivir, the newest drug in this class, is given as a single IV dose for patients with uncomplicated influenza who have been sick for 2 days or less. Peramavir is approved for patients 2 or older. This is a particularly great choice for a vomiting patient. Nachi: And as you mentioned before, just last month, the FDA approved baloxavir, a single dose antiviral. It’s effective for influenza type A or B. Note that safety and efficacy have not been established for patients less than 12 years old, weighing less than 40 kg, or pregnant or lactating patients. Jeff: Unfortunately, there has been some pretty notable antiviral resistance in the recent past, moreso with the adamantane class, but recently also with the neuraminidase inhibitors. In 2007-2008, an oseltamivir-resistant H1N1 strain emerged globally. Luckily, cross-resistance between baloxavir and the adamantanes or neuraminidase inhibitors isn’t expected, as they target different viral proteins, so this may be an answer this year, and in the future. Nachi: Let’s talk chemoprophylaxis for influenza.. Chemoprophylaxis with oseltamavir or zanamavir can be considered for patients who are at high risk for complications and were exposed to influenza in the first 2 weeks following vaccination, patients who are at high risk for complications and cannot receive the vaccination, and those who are immunocompromised. Jeff: Chemoprophylaxis is also recommended for pregnant women. For postexposure prophylaxis for pregnant women, the current recommendation is to administer oseltamivir. Nachi: We should also discuss the efficacy of treatment with antivirals. This has been a hotly debated topic, especially with regards to cost versus benefit… In a meta-analysis, using time to alleviation of symptoms as the primary endpoint, oseltamavir resulted in an efficacy of 73% (with a wide 95% CI from 33% to 89%). And this was with dose of 150mg/day in a symptomatic influenza patient. Jeff: Similarly zanamavir given at 10mg/day was 62% effective, but again with a wide 95% CI from 15% to 83%. And, of note, other studies have looked into peramivir, but have found no significant benefits other than the route of delivery. Nachi: In another 2014 study by Muthuri et al., neuraminidase inhibitors were associated with a reduction in mortality -- adjusted OR = 0.81 (with a 95% CI 0.70 to 0.93). Also when comparing late treatment with early treatment (that is, within 2 days of symptom onset), there was a reduction in mortality risk with adjusted OR 0.48 (95%CI 0.41-0.56). These associations with reduction in mortality risk were less pronounced and less significant in children. Jeff: Mortality benefit, not bad! They further found an increase in mortality hazard ratio with each day’s delay in initiation of treatment up to 5 days, when compared to treatment initiated within 2 days. Nachi: But back to the children for a second -- another review of neuraminidase inhibitors in children < 12 years old found duration of clinical symptoms was reduced by 36 hours among previously healthy children taking oseltamivir and 30 hours by children taking zanamivir. Jeff: I think that’s worth summarizing - According to this month’s author’s review of the best current evidence, use of neuraminidase inhibitors is recommended, especially if started within 2 days, for elderly patients and those with comorbidities. Nachi: Seems like there is decent data to support that conclusion. But let’s not forget that these medications all have side effects. Jeff: These drugs actually tend to be well tolerated.The most frequently noted side effect of oseltamavir is nausea and vomiting, while zanamavir is associated with diarrhea. Nachi: Amazing. Let’s talk disposition for your influenza patient. Jeff: Disposition will depend on many clinical factors, like age, respiratory status, oxygen saturation, comorbid conditions, and reliability of follow up care. Admission might be needed not only to manage the viral infection, but also expected complications. Nachi: If you’re discharging a patient, be sure to engage in shared decision making regarding risks and benefits of available treatments. Ensure outpatient follow up and discuss return to er precautions. Jeff: Also, the CDC recommends that these patients stay home for at least 24 hours after their fever has broken. Nachi: With that -- Let’s summarize the key points and clinical pearls from this month’s issue J: Even though influenza vaccine effectiveness is typically only 50%, this still translates to a decrease in influenza-related morbidity and mortality. 2. The CDC defines influenza-like illness as a temperature > 100 F with either cough or sore throat, in the absence of a known cause other than influenza. 3. When influenza is suspected in the prehospital setting, patients and providers should wear face masks to avoid spreading the virus. 4. In the emergency department, standard isolation and droplet precautions should be maintained for suspected or confirmed infections. 5. The most common symptoms of influenza in adults are cough, fatigue, nasal congestion, and fever. Sneezing is a negative predictor in adults. 6. In children, the most common presenting symptoms are fever, cough, and rhinitis. Vomiting and diarrhea is also more common in children than adults. 7. Rapid testing and identification results in decreased delays in treatment and management decisions. 8. During peak flu season, clinical judgement may be as good as rapid testing, making rapid testing less necessary. J: Rapid testing may be more beneficial in times of lower disease prevalence. 10. Empiric treatment of critically ill patients should be considered even if rapid testing is negative. J: For mild to moderate disease and no underlying high-risk conditions, supportive therapy is usually sufficient. 12.For more ill patients or those at substantial risk for complications, consider antiviral treatment. 13.Oseltamivir is approved for patients of all ages, and reduces the length of symptoms by one day. 14.When treating influenza, peramivir is an ideal agent for the vomiting patient. 15.Baloxavir is a new single-dose antiviral agent approved by the FDA in October 2018. It works in a novel way and is effective for treatment of influenza A and B. 16.Chemoprophylaxis with oseltamivir or zanamivir should be considered in patients who are immunocompromised or patients who are at elevated risk for complications and cannot receive the vaccination. 17.Consider oseltamivir as post exposure prophylaxis in pregnant women. 18.Neuraminidase inhibitors are associated with decreased duration of symptoms and complications, especially if started within 2 days of symptom onset. J: So that wraps up episode 23 - Influenza: Diagnosis and Management in the Emergency Department. N: Additional materials are available on our website for Emergency Medicine Practice subscribers. For our subscribers: be sure to go online to get your CME credit for this issue, which includes 3 pharmacology CME credits. J: Also, for our NP and PA listeners, we have a special offer this month: You can get a full year of access to Emergency Medicine Practice for just $199--including lots of pharmacology, stroke, and trauma CME--and so much more! To get this special deal, go to www.ebmedicine.net/APP. Again, that’s www.ebmedicine.net/APP. N: If you’re not a subscriber, consider joining today. You can find out more at www.ebmedicine.net/subscribe. Subscribers get in-depth articles on hundreds of emergency medicine topics, concise summaries of the articles, calculators and risk scores, and CME credits. You’ll also get enhanced access to the podcast, including the images and tables mentioned. You can find everything you need to know at ebmedicine.net/subscribe. J: And the address for this month’s credit is ebmedicine.net/E1218. As always, the you heard throughout the episode corresponds to the answers to the CME questions. Lastly, be sure to find us on iTunes and rate us or leave comments there. You can also email us directly at emplify@ebmedicine.net with any comments or suggestions. Talk to you next month!    

#026 - Eco ModernismWe take a look at the Eco-Modernist movement.With Special guests:Rauli Partanen (BBA) is an author, an entrepreneur and a father of three. His first book Suomi öljyn jälkeen(with Harri Paloheimo and Heikki Waris) got shortlisted for both of Finlands large national non-fiction book awards. Its adapted translation The World After Cheap Oil was published by Routledge in late 2014, with a German translation (self-published) Die Welt nach dem billigen Öl following in early 2015. Rauli also writes articles on different papers and magazines and gives frequent lectures, presentations and interviews on the subjects of his expertise (energy in general and as a enabler of economic activity and well-being and environmental problems such as climate change, oil and nuclear energy especially, resource scarcity and so forth).Twitter: @kaikenhuippuLinkedin: fi.linkedin.com/in/raulipartanenBlog: kaikenhuippu.com (mainly in finnish)Vance Crowe is the Director of Millennial Engagement at Monsanto in Saint Louis, Missouri. Vance is a former Communications Strategist for the World Bank Group, a returned U.S. Peace Corps Volunteer stationed in Kenya, a former communications coordinator at a National Public Radio (NPR) affiliate in Northern California and was a deckhand on an eco-tourism ship that traveled in the Western Hemisphere. Vance holds an undergraduate degree in communications from Marquette University and a Master's Degree in Cross-Cultural Negotiations from the Seton Hall School of Diplomacy.Connect with Vance on twitter @VanceCroweAnd the TwL team for this episode:Nathan Dickey: @TheNatheistJenn: @PhotoJennBoMichael Kitching: @Bio_InspirationCal: @ZuluCalEcoModernist Manifesto: http://www.ecomodernism.org/Like the show? Support us on patreon :- http://www.patreon.com/trollingwithlogicTWL website : http://www.trollingwithlogic.com/TWL facebook group : http://on.fb.me/TZwgy3TWL twitter : https://twitter.com/TrollingWLogicTWL facebook page : http://on.fb.me/1Eq3b8kSubscribe to the podcast:-Feedburner: http://tinyurl.com/twl-feed-burnItunes : http://tinyurl.com/twl-itunesStitcher : http://tinyurl.com/twl-stitcher Podbean : http://tinyurl.com/twl-podbeanPodfeed : http://tinyurl.com/twl-podfeed

When most people are injured in car wrecks or at work, they can't afford to pay a lawyer an hourly fee out of pocket to win their case against a large corporation or their insurance company. That's why attorneys for the plaintiffs in these lawsuits use a contingency fee, which pays the lawyer about a third of the total settlement or verdict -- but only if the plaintiff wins. That amount covers the work done by the lawyers, and compensates them for the risk of no payout. In this episode, Dan Minc, a 1977 graduate of Seton Hall School of Law, discusses how he managed to rise up to his firm's managing partner after starting there as a first-year lawyer. He also talks about how he builds his book of business and what he assesses when determining whether to take a client. After all, he's only paid if his client wins. This episode is hosted by Derek Tokaz, an academic writing teacher at American University. It is sponsored by ShouldIBeALawyer.com and Top-Law-Schools.com. Episode Links Contingency Fee Alternative: Legal Expenses Insurance Rosenberg, Minc, Falkoff, & Wolff Daniel Minc Profile

In this episode, Susan interviews Dr. Andrea Bartoli, someone who takes important professional risks to get good work done. Dr. Bartoli is currently Dean at Seton Hall School of Diplomacy and International Relations and an incredibly brave, intelligent and collaborative soul. He has been part of peacemaking initiatives in Mozambique, Guatemala, Algeria, Kosovo, Burundi, Democratic Republic of the Congo, Burma/Myanmar, East Timor, Colombia, and has been an advocate of innovative processes to build common ground in the university systems in which he has spent most of his professional career. In this podcast, he tells the story of his contribution in Mozambique to bring about the end of a 16-year civil war. This work, he says, was the most important and formative of his long career in the field of peacemaking. Instrumental to the success of the endeavor was a strong belief that, in spite of the huge challenges, peace was possible. As Dr. Bartoli says, “Peace is always possible. This must be repeated over and over in situations where you do not see the possibility of peace. . .If peace was possible in Mozambique, then it is possible in Syria, Afghanistan, it is possible everywhere.” The story of Mozambique started simply – giving assistance to just one friend. That friend, in turn was connected to expanding systems of people, ultimately to an entire country and then, by way of example, to the world. Dr. Bartoli reflects how “each of us has a daily decision to make regarding how we use ourselves to evolve systems to a more harmonious and constructive place.” And, he says, “I think that the human spirit is much stronger than war, much stronger than violence. I think that violence and war are mistakes, collective mistakes, of not applying yourself to the discipline of seeking what unites and not what divides.” Towards the end of the interview, Dr Bartoli talks about the importance of innovative process choice in peacemaking and diplomacy, and for the “diplomacy” required to run large complex systems such as universities.

Like the show? Support us on patreon :- http://www.patreon.com/trollingwithlogic As part of our  #GMMarch   season we take a look the agriculture corporation Monsanto with special guest Vance Crowe, Director of Millennial Engagement. How do you engage the public and communicate effectively about a company like Monsanto?  Vance is a former Communications Strategist for the World Bank Group, a returned U.S. Peace Corps Volunteer stationed in Kenya, a former communications coordinator at a National Public Radio (NPR) affiliate in Northern California and was a deckhand on an eco-tourism ship that traveled in the Western Hemisphere. Vance holds an undergraduate degree in communications from Marquette University and a Master's Degree in Cross-Cultural Negotiations from the Seton Hall School of Diplomacy. http://www.monsanto.com/whoweare/page... https://twitter.com/vancecrowe Monsanto Company is a publicly traded American multinational agrochemical and agricultural biotechnology corporation headquartered in Creve Coeur, Greater St. Louis, Missouri. It is a leading producer of genetically engineered (GE) seed and Roundup, a glyphosate-based herbicide. Monsanto's role in agricultural changes, biotechnology products, lobbying of government agencies, and history as a chemical company have made the company controversial. TWL website : http://www.trollingwithlogic.com/ TWL facebook group : http://on.fb.me/TZwgy3 TWL twitter : https://twitter.com/TrollingWLogic TWL facebook page : http://on.fb.me/1Eq3b8k Subscribe to the podcast:- Feedburner: http://tinyurl.com/twl-feed-burn Itunes         : http://tinyurl.com/twl-itunes Stitcher       : http://tinyurl.com/twl-stitcher  Podbean     : http://tinyurl.com/twl-podbean Podfeed      : http://tinyurl.com/twl-podfeed

A talk show on KZSU-FM, Stanford, 90.1 FM, hosted by Center for Internet & Society Resident Fellow David S. Levine. The show includes guests and focuses on the intersection of technology and society. How is our world impacted by the great technological changes taking place? Each week, a different sphere is explored. This week, David interviews Profs. Danielle Citron of University of Maryland School of Law and Frank Pasquale of Seton Hall School of Law discussing Fusion Centers. For more information, please go to http://hearsayculture.com.

Leadership New Jersey's goal is to expand and improve the pool of the state's civic leaders. The program, founded in 1986, honors men and women who combine a successful career with leadership in serving their communities. As part of its programming, Leadership New Jersey sponsors the Forum on the Future of New Jersey, an annual conference devoted to dealing with the key issues facing New Jersey. This year, in conjunction with the Forum, Leadership New Jersey is pleased to introduce podcasts from the Forum. In this podcast, we present a panel discussion of "Who Decides How We Spend Our Money." Moderator: Paula Franzese, LNJ ‘93 Professor of Law, Seton Hall School of Law and Chair, NJ State Ethics Commission Nationally acclaimed for her teaching, Professor Franzese was appointed Chair of the State Ethics Commission by the Governor after serving on his Ethics and Policy Management Task Force. Paula's casebook, “Property Law and the Public Interest,? is recognized as one of the first to expansively explore the public interest dimensions of Property Law. Lee Carlson Publisher, NJBIZ D. Lee Carlson has spent more than thirty years in the newspaper business in Northern California, at publications such as the San Francisco Chronicle and the San Jose Mercury News, before coming to the east coast two years ago. She is the publisher of NJBIZ, the only weekly business-to-business publication in New Jersey. Richard J. Codey President, NJ State Senate The current Senate President and former Acting Governor of New Jersey, Senator Codey's career in state government has spanned more than three decades. As a Senator, he chaired the Institutions, Health, and Welfare Committee and has earned a reputation for supporting the mentally ill as well as improving healthcare through the New Jersey's Healthcare Reform Act. Hal Garwin, LNJ ‘95 President/Executive Director, Community Health Law Project Hal is a West Orange resident and graduate of Rutgers University Camden School of Law. A former Legal Services Attorney, he is currently the Chair of the Board of NJ SHARES, Vice President of the Mental Health Association in NJ, and Chair of the Board of Arts Unbound. Ralph Izzo President and COO, PSE&G Since joining PSE&G in 1992, Ralph has been elected to several senior executive positions. He also served four years as a senior policy advisor in the Office of New Jersey Governor Thomas H. Kean, as well as currently serving on the board of directors for the New Jersey Chamber of Commerce and the New Jersey Utilities Association. Leonard Lance Minority Leader, NJ State Senate Senator Lance was elected to the Senate and reelected in 2003, serving as Minority Leader since 2004. He was born and raised in Hunterdon County, earning a bachelor's degree from Lehigh University and a master's degree from the Woodrow Wilson School of Public and International Affairs of Princeton University. Download the podcast here (52.4 mb mono MP3 file, 57:15 duration).